focus -WSS

focus

author：knowledge 2025-09-03 03:17:50 - browse：4418

Stock exchange — Drew Angerer/Getty Images

Viking Therapeutics said Tuesday that its closely watched oral obesity drug had succeeded in an early-stage trial and that it planned to advance the medicine into the next phase of development.

The top-line results released Tuesday were only from a Phase 1 study, which primarily focuses on a drug’s safety. But Viking said that in the study, its medicine led to a roughly 3.3% placebo-adjusted average weight loss after four weeks and that it showed no safety issues.

In preview notes, analysts had said that investors would want to see between 3% and 4% placebo-adjusted weight loss. Shares of San Diego-based Viking were up more than 20% in pre-market trading Tuesday.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： State Dept. review finds Biden bears some blame for Afghanistan failures
Next article： Biden declares emergency in flood

WSS

GSK to buy asthma

Eisai exec who led development of Alzheimer’s drug to retire

Home health providers sue Medicare over payment cuts

Giraffe named Twiga, who was among the oldest cared for by humans, died at age 31 at East Texas zoo

Three issues to watch in global health in 2024

The SUPPORT Act is critical to fighting the opioid crisis

Wikipedia

focus

leisure time

23andMe had bad news about my health. I wish a person had delivered it

Accuser who called Kevin Spacey 'vile sexual predator' admits he joked about incident

Drug repurposing or repositioning? The language matters

Bank of America ordered to pay more than $100 million for double charging fees, withholding rewards

Dobbs anniversary: the lost opportunity of abortion as health care

Rikers Island jail violence not addressed, NYC should be held in contempt: Fed monitor

Medicare proposal to cover medical devices draws a mixed reaction

Doulas covered by Medicaid under New York's new plan

ChatGPT in medicine: STAT answers readers' burning questions

Generative AI mines health records to identify patients’ social needs

knowledge

JPM 2024: Verve Therapeutics looks to mainstream genome editing

Tulsa Race Massacre survivors and attorneys respond to dismissal of lawsuit

Bank of America ordered to pay more than $100 million for double charging fees, withholding rewards

GSK to buy asthma

The U.S. needs a new definition of substance use “recovery”

Biotech reporter’s notebook: A sunnier mood at JPM 2024

focus

hotspot

hotspot

explore